Jaguar Health, Inc. (JAGX) Stock

Jaguar Health, Inc. (JAGX) is a Healthcare stock trading at $0.87 (as of 2026-08-21), with a market capitalization of $1.01M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Jaguar Health, Inc. is a commercial-stage pharmaceutical company developing and marketing prescription treatments for gastrointestinal disorders, including noninfectious diarrhea, for both people and animals. It operates Human Health and Animal Health segments, including Mytesi for adults with HIV/AIDS on antiretroviral therapy, and develops Crofelemer and other candidates for additional diarrhea-related indications in humans and dogs.

Understand Jaguar Health, Inc.: how it makes money

Jaguar Health develops prescription medicines for people and animals with gastrointestinal distress, focusing on chronic, debilitating diarrhea, and it makes money by marketing products such as Mytesi for symptomatic relief and developing Crofelemer for additional diarrhea-related indications.

The profit engine is product commercial activity and indication expansion around diarrhea care, with Human Health tied to Mytesi (symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy) and Animal Health tied to the company’s broader diarrhea-focused prescription medicine development.

Revenue by segment (latest quarter)
Human Health	$0.0B
Animal Health	$0.0B

Business quality (Exceptional): Clear segment structure (Human Health and Animal Health) and a focused commercial and development thesis around diarrhea indications, but the provided facts do not include operating KPIs or a segment revenue breakdown, limiting how precisely investors can track execution.

Bull case

Targeted, defined therapeutic focus: The company develops prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
A marketed product with a specific human indication: Jaguar Health markets Mytesi for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Indication expansion potential from Crofelemer: Crofelemer is developed for multiple possible follow-on indications, including cancer therapy-related diarrhea, and orphan-drug indications for symptomatic relief of diarrhea in additional settings.

Bear case

Dependence on narrow clinical areas: The business is centered on diarrhea-related indications, which may limit growth if demand or access depends on specific patient populations and treatment contexts.
Execution risk around follow-on indications: While Crofelemer has multiple possible follow-on indications, progress depends on successful development toward those indications, which is not supported by any operating metric in the provided facts.
Limited visibility from provided operating data: The provided facts do not include operational KPIs investors commonly track for this company, which makes it harder to assess execution drivers from the information given.

Valuation — source: SEC EDGAR (first-party)
Price	$0.87
Market Cap	$1.01M

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$11.51M
Net Margin	-465.4%
Return on Equity	-747.5%
Current Ratio	0.69
Revenue Growth (YoY)	-58.9%
EPS Growth (YoY)	53.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-18.88 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($60098.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Lisa A. Conte
Employees	49
Country	US
IPO Date	2015-05-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.